BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Biopta Increase Its Sources Of Fresh Human Biomaterials


7/17/2009 9:19:01 AM

Glasgow, UK, 17th July 2009: Biopta Ltd, the human tissue-based contract research organisation, today announced a major development in client delivery with an increased supply of functional human hearts.

Ex vivo human tissue studies play a key part in drug development, providing pharmaceutical & biotechnology companies with a more predictive human model earlier in the development process. Many of the companies Biopta work with have up until now depended solely on animal models, however with Biopta’s access to fresh functional human biomaterials this type of early human tissue testing is becoming more routine. Today Biopta announced that their supply of ethically-donated fresh human hearts has dramatically increased to an average of 2-3 per week.

Dr David Bunton Biopta’s CEO said ‘this increased supply of fresh human heart tissue is having a dramatic effect on Biopta’s business; we are now able to turnaround cardiovascular safety studies for our clients in 4 to 6 weeks rather than the previous delivery of 4 months. With this type of supply I’m very excited about Biopta’s growth moving forward’.


Read at BioSpace.com

Biopta
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES